Andrew Baum
Stock Analyst at Citigroup
(2.87)
# 1,745
Out of 4,735 analysts
58
Total ratings
70.73%
Success rate
13.53%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $55 → $60 | $57.04 | +5.19% | 10 | Nov 12, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $30.30 | +32.01% | 2 | Oct 25, 2024 | |
| MRK Merck & Co. | Maintains: Buy | $140 → $130 | $96.24 | +35.08% | 11 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $172.61 | +24.56% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly | Maintains: Buy | $675 → $895 | $742.35 | +20.56% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $13.36 | -25.15% | 3 | Oct 20, 2023 | |
| PFE Pfizer | Maintains: Neutral | $42 → $35 | $26.64 | +31.38% | 9 | Oct 16, 2023 | |
| GSK GSK | Downgrades: Neutral | n/a | $33.78 | - | 2 | Jul 5, 2017 |
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Neutral
Price Target: $55 → $60
Current: $57.04
Upside: +5.19%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $30.30
Upside: +32.01%
Merck & Co.
Oct 25, 2024
Maintains: Buy
Price Target: $140 → $130
Current: $96.24
Upside: +35.08%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $172.61
Upside: +24.56%
Eli Lilly
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $742.35
Upside: +20.56%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $13.36
Upside: -25.15%
Pfizer
Oct 16, 2023
Maintains: Neutral
Price Target: $42 → $35
Current: $26.64
Upside: +31.38%
GSK
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $33.78
Upside: -